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ORIGINAL ARTICLE
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Joris F. Ooms, MD; Maarten P. van Wiechen, MD; Marcel L. Geleijnse, MD, PhD; Felix Zijlstra, MD, PhD;  
Joost Daemen, MD, PhD; Nicolas M. Van Mieghem, MD, PhD; Francesco U.S. Mattace-Raso, MD, PhD;  
Mattie J. Lenzen, PhD; Peter P.T. de Jaegere, MD, PhD
BACKGROUND: In aortic stenosis, valvulo-arterial impedance (Zva) estimates the overall left ventricular afterload (valve and 
arterial component). We investigated the association of Zva (≥5 versus <5 mm Hg mL−1 m−2) on quality of life (QOL) and 
exercise performance (EP) ≥1 year after transcatheter aortic valve replacement (TAVR).
METHODS: The study population consists of 250 TAVR patients in whom baseline Zva and follow-up QOL was prospectively 
assessed using EuroQOL-5-dimensions instruments; EP was assessed in 192 patients who survived ≥1 year after TAVR 
using questionnaires related to daily activities. In 124 patients, Zva at 1-year was also available and was used to study the 
change in Zva (baseline to 1 year) on QOL/EP.
RESULTS: Elevated baseline Zva was present in 125 patients (50%). At a median of 28 (IQR, 17–40) months, patients with 
elevated baseline Zva were more limited in mobility (88% versus 71%; P=0.004), self-care (40% versus 25%; P=0.019), and 
independent daily activities (taking a shower: 53% versus 38%, P=0.030; walking 100 meter: 76% versus 54%, P=0.001; 
and walking stairs: 74% versus 54%, P=0.011). By multivariable analysis, elevated Zva predicted unfavorable QOL (lower 
EuroQOL-5-dimensions-Utility Index, odds ratio, 1.98; CI, 1.15–3.41) and unfavorable EP (any limitation in ≥3 daily activities, 
odds ratio, 2.55; CI, 1.41–4.62). After TAVR, the proportion of patients with elevated Zva fell from 50% to 21% and remained 
21% at 1 year and was found to be associated with more limitations in mobility, self-care, and daily activities compared with 
patients with Zva <5 mm Hg mL−1 m−2.
CONCLUSIONS: Elevated Zva was seen in half of patients and predicted unfavorable long-term QOL and EP. At 1 year after 
TAVR, the prevalence of elevated Zva was 21% but remained associated with poor QOL/EP.
VISUAL OVERVIEW: A visual overview is available for this article.
Key Words: aortic valve ◼ arterial pressure ◼ echocardiography ◼ quality of life ◼ transcatheter aortic valve replacement
Aortic stenosis (AoS) is a common valvular heart disease associated with a poor prognosis if left untreated.1–3 The hemodynamic effects of AoS 
consist of increased left ventricular (LV) afterload, 
reduced myocardial compliance, and increased myo-
cardial workload.2,3 Transcatheter aortic valve replace-
ment (TAVR) effectively reduces afterload and wall 
stress and improves survival and health-related quality 
of life (QOL).4–7
However, not all patients benefit from TAVR. This may 
in part be explained by the fact that the excess in after-
load in patients with AoS is not only caused by the valve 
but also by a reduction in arterial compliance.8 The latter 
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of a systemic atherosclerotic process involving all parts of 
the arterial tree.9,10 Age-related structural changes of the 
arterial wall result in reduced compliance that becomes 
particularly manifest in the elderly.11 As a result, the LV in 
patients with AoS is exposed to a valvular load caused 
by the obstructive valve and an arterial load imposed by 
a decrease in systemic arterial compliance.8 Previous 
studies demonstrated that the global LV hemodynamic 
load can be estimated using an index that quantifies the 
sum of the valvular and vascular load, the valvulo-arterial 
impedance (Zva).8,12 This parameter has shown to pre-
dict LV systolic and diastolic dysfunction8 and mortality in 
patients with moderate AoS and in patients with severe 
AoS who underwent TAVR.13,14 Yet, the impact of Zva on 
health-related QOL and exercise performance (EP) after 
TAVR is unknown and was subject of this observational 
study encompassing 250 patients. In addition, we stud-
ied the changes in Zva early (ie, baseline discharge) and 
late (ie, >1 year) after TAVR and its association with QOL 




From January 2014 until June 2017, a total of 437 patients 
with symptomatic severe AoS underwent TAVR in the Erasmus 
Medical Center, Rotterdam, the Netherlands. The association of 
Zva and long-term QOL was assessed in 250 patients, includ-
ing 58 patients who died during follow-up (details in statistical 
analyses; cohort 1A, Figure). The association of Zva and EP 
was assessed in 192 patients surviving ≥1 year after TAVR 
(cohort 1B). The secondary objective (changes in Zva and effect 
on QOL) was studied in 124 patients with echocardiographic 
examination at baseline, post-TAVR and at 1 year (cohort 2). All 
patients were enrolled in the multidisciplinary TAVR Care and 
Cure program described elsewhere, which consists of a multi-
disciplinary assessment, treatment decision, and treatment in 
addition to a structured in-hospital and post discharge follow-
up using prospective collection of a comprehensive set of pre-
defined variables.15 In short, all patients undergo a full medical 
history inventory including antecedent events, current comorbid 
conditions, and symptoms (New York Heart Association [NYHA], 
Canadian Cardiovascular Society class) followed by clinical 
evaluation and examination by the geriatrician using the TAVR 
Care and Cure protocol in which all measures and variables to 
be collected are defined. Among others, frailty was collected and 
defined by an Erasmus Frailty Score ≥3 which has been shown 
to predict delirium and mortality late after TAVR.15 Cardiovascular 
imaging includes cardiac ultrasound, coronary angiography, and 
multislice computed tomography for the assessment of techni-
cal suitability and access site.16,17 All patients are subsequently 
discussed in the multidisciplinary heart-team meeting consisting 
of interventional cardiologists, cardiac surgeons, an echocar-
diographist, and a geriatrician.18 The study was approved by the 
institutional review committee, and all patients provided informed 
consent at the end of the pre-TAVR outpatient clinic visit during 
which the objective of anonymous data collection in the frame-
work of the TAVR Care and Cure protocol were explained. The 
data, methods, and materials used to conduct the study will not 
be made available to other researchers for the purpose of repro-
ducing the results or replication the procedure used to conduct 
the study. This study complies with the Declaration of Helsinki.
Echocardiography
Two-dimensional (Doppler) echocardiography was performed 
at baseline, post-TAVR (before discharge) and at 1-year fol-
low-up using a Philips iE33 or a Epiq7 system (Philips, Best, 
the Netherlands) with the patient in a left lateral decubitus 
position. Standard echocardiographic evaluation of AoS 
severity was assessed according to European Association 
of Echocardiography/American Society of Echocardiography 
recommendations.19 The aortic jet velocity was assessed in 
various acoustic windows, and aortic valve area was calcu-
lated using the continuity equation.19 Systolic LV function 
Nonstandard Abbreviations and Acronyms
AoS aortic stenosis
BNP B type natriuretic peptide
EP exercise performance
LV left ventricular
NYHA New York Heart Association
OR odds ratio
QOL quality of life
SVI stroke volume index
TAVR transcatheter aortic valve replacement
Zva valvulo-arterial impedance
WHAT IS KNOWN
• In aortic stenosis, valvulo-arterial impedance (Zva) 
estimates global left ventricular afterload imposed 
by the valve and reduced arterial compliance, and 
predicts mortality after transcatheter aortic valve 
replacement (TAVR).
WHAT THIS STUDY ADDS
• This study prospectively assessed the association 
between baseline Zva and health-related quality of 
life and exercise performance ≥1 year after TAVR 
and explored the changes in Zva before, after, and 
at 1 year after TAVR and its association with long-
term quality of life.
• Elevated Zva was found in 50% of patients before 
and 21% after TAVR and remained 21% at 1-year 
follow-up.
• Baseline elevated Zva independently predicted 
unfavorable quality of life and exercise performance 
at a median of 28 months after TAVR.
• Patients with persistent elevated Zva at 1 year after 
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was assessed according to biplane modified Simpson rule, 
and diastolic function was assessed according to the 2016 
American Society of Echocardiography/European Society 
of Cardiovascular Imaging guidelines.20 LV dimensions were 
obtained in the parasternal long-axis view as previously 
described6; LV mass was calculated using the Devereux for-
mula21 and indexed to body surface area (LV mass index). LV 
stroke volume was calculated in the LV outflow tract from the 
pulsed wave Doppler recordings and indexed to body surface 
area (stroke volume index [SVI]).
Hemodynamic Parameters
The global LV hemodynamic load was estimated using Zva 
defined by the sum of the mean transaortic gradient and the 
systolic blood pressure divided by the LV SVI.8 The systolic 
blood pressure (using an arm-cuff sphygmomanometer) and 
heart rate were recorded after at least 3 minutes supine posi-
tion for the assessment of baseline Zva; the assessment of 
Zva post-TAVR and at 1 year was done using blood pressure 
measurements at the bedside before discharge and at 1-year 
outpatient clinic visits, respectively. A cutoff value for Zva of 
5 mm Hg mL−1 m−2 was taken on the basis of prior studies 
that showed favorable outcomes in case of a low Zva (Zva <5 
mm Hg·mL−1·m−2) as compared with a high Zva (Zva ≥5 mm·Hg 
mL−1·m−2).8,13,14 Pulse pressure was defined by the difference 
between systolic and diastolic arterial blood pressure; systemic 
vascular resistance was calculated by the ratio of 80×mean 
arterial pressure divided by the cardiac output. Systemic arterial 
compliance was defined by the ratio of SVI to pulse pressure22; 
total arterial load was approximated using the effective arte-
rial elastance index and estimated by the formula 0.9×systolic 
arterial blood pressure/SVI.23
Follow-Up, QOL, and EP
First, survival status was checked using the Dutch Civil Registry. 
After confirmation of survival, QOL/EP was measured in 
patients who survived ≥1 year after TAVR using the EuroQOL-
5-dimensions-5 levels questionnaires, the NYHA functional 
classification in addition to questions related to physical fitness 
(taking a shower, walking 100 meter, walking 1 flight of stairs, 
and gardening).
The EuroQOL-5-dimensions-5 levels comprises 5 dimensions: 
mobility, self-care, usual activities, pain/discomfort and anxiety/
depression.24–26 Each dimension has 5 levels (no, slight, mod-
erate, severe, and extreme problems) by which a unique health 
state per item is determined. These health states are converted 
into weighted health states (EQ-5D utility index) by applying 
scores on which full health has a value of 1 and death a value of 
0. Therefore, patients who died before QOL assessment (n=58) 
were assigned an EQ-5D utility index of 0, a method used similar to 
the approach by Arnold et al27 for the Kansas City Cardiomyopathy 
Questionnaire. Using the same methodology as Grandy and Fox28 
an ordinal variable for the EQ-5D Utility Index was created by cat-
egorizing the continuous variable into 4 levels for the purpose of 
regression analyses, with level 1 and 4 corresponding to (most) 
favorable versus unfavorable QOL, respectively.
In patients who survived ≥1 year after TAVR (n=192), EP 
was assessed by the Exercise Limitation Index which is com-
posed of a summary score with 1 point assigned per limitation 
in daily activity out of the 5 items that were significantly associ-
ated with Zva ≥5 mm·Hg mL−1·m−2 (mobility, self-care, shower-
ing, walking 100 meter, and walking stairs). Participants were 
classified as having an Exercise Limitation Index ranging from 
0 to 5, with level 0 and 5 corresponding to (most) favorable 
Figure. Patient selection flow chart.  
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versus unfavorable EP, respectively. QOL/EP data were not 
complete at baseline and are not included in the analysis.
For the assessment of serial changes in Zva (baseline, post-
TAVR, 1 year after TAVR), we performed a sub-analysis in 124 
patients with a complete set of data of both echocardiography/
Zva and QOL assessment ≥1 year after TAVR allowing paired 
analyses. Compared with the 126 patients excluded from this 
analysis, the included 124 patients were less symptomatic and 
at lower operative risk (NYHA class ≥3: 58% versus 76%; 
EuroScore: 15% versus 20%), and showed better systolic and 
diastolic LV function in addition to a better renal function (ejec-
tion fraction 56% versus 52%; diastolic dysfunction 35% ver-
sus 52%; and creatinine 133 versus 100 mmol/L; Table I in the 
Data Supplement).
Statistical Analysis
Categorical variables are presented as frequencies and percent-
ages and were compared with the χ2 test or Fisher exact test. 
Normality of distributions was assessed with the Shapiro Wilk test. 
Normal and skewed continuous variables are presented as means 
(SD) and medians (interquartile range), respectively. Continues 
variables were compared using the Student t test, Mann Whitney 
U test, or Wilcoxon rank-sum test when appropriate.
We applied ordinal logistic regression analyses with Zva as the 
independent (continuous) variable and unfavorable QOL (mea-
sured by EQ-5D Utility Index, ordinal variable) as the dependent 
variable (cohort 1A). Analyses were then repeated with inclu-
sion restricted to surviving patients ≥1 year post-TAVR (cohort 
1B), with unfavorable QOL and unfavorable EP (measured by 
Exercise Limitation Index, ordinal variable) as the dependent vari-
ables. The results are presented as odds ratios with 95% CIs. 
All analyses were adjusted for variables known to be associated 
with Zva, QOL, and EP: age, gender, COPD, peripheral vascular 
disease, aortic valve area, baseline NYHA functional class, frailty, 
and time to death or measurement of QOL/EP.
Changes in continuous variables from baseline until follow-up 
were compared using 1-way repeated measures ANOVA (within-
subjects ANOVA). All statistical analyses were performed using 
Statistical Package for Social Science for Windows version 21. 
Two sided P values <0.05 were considered statistically significant.
RESULTS
Baseline Characteristics
Clinical baseline-, echocardiographic-, and hemodynamic 
characteristics of the total population and in patients 
with normal and elevated impedance (ie, Zva <5 and 
≥5 mm Hg mL−1·m−2) are presented in Tables 1 and 2. 
An elevated impedance (Zva ≥5 mm Hg mL−1·m−2) was 
observed in 125 patients (50%) who—in comparison to 
those with normal impedance—had a higher prevalence 
of atrial fibrillation (42% versus 28%; P=0.024) and 
falling incidents (33% versus 21%; P=0.032), but less 
frequent use of calcium antagonists and ≥3 antihyper-
tensive agents (16% versus 29%; P=0.017 and 10% 
versus 21%; P=0.023, respectively).
Also, patients with a Zva ≥5 mm Hg mL−1·m−2 had a 
lower LV ejection fraction, SVI, cardiac index, and a lower 
systemic arterial compliance (51±13% versus 57±12%, 
P=0.001; 30±7 versus 44±9 mL/m2, P<0.001 and 
0.44±0.13 versus 0.68±0.22 mL−1·m−2 mm Hg, P<0.001, 
respectively) and a higher heart rate (71±12 versus 
67±11, P=0.006), MAP (102±14 versus 93±12 mm Hg, 
P<0.001), systemic vascular resistance (2167±596 ver-
sus 1449±312 dyne·s·cm−5, P<0.001), and total arterial 
load (4.7±1.0 versus 2.9±0.5 mm Hg mL−1·m−2, P<0.001). 
Their outflow tract diameter (21±2 versus 22±2 mm, 
P<0.001) was smaller as well as their aortic valve area 
(0.66±0.17 versus 0.84±0.20 cm2, P<0.001) as com-
pared with patients with Zva <5 mm Hg mL−1·m−2.
Long-Term QOL and EP
Table 3 summarizes long-term QOL and EP data in 
patients with normal and elevated Zva. In an analyses 
including all patients, those with Zva ≥5 mm Hg mL−1·m−2 
showed a trend towards unfavorable QOL as compared 
with patients with Zva <5 mm Hg·mL−1·m−2 (median 
EQ-5D Utility Index: 0.69 versus 0.77, P=0.12). In a 
repeated analyses restricted to surviving patients ≥1 year 
post-TAVR, this association became more apparent but 
did not reach statistical significance (EQ-5D Utility Index: 
0.75 versus 0.80, P=0.056). With respect to EP, patients 
with Zva ≥5 mm Hg·mL−1·m−2 more frequently reported 
limitations in mobility (88% versus 71%, P=0.004), self-
care (40% versus 25%, P=0.019) and daily activities 
including taking a shower (53% versus 38%, P=0.030), 
walking 100 meter (76% versus 54%, P=0.001), and 
walking 1 flight of stairs (74% versus 54%, P=0.011) 
resulting in a lower Visual Analogue Score (70 versus 
75 points, P=0.048) and a worse Exercise Limitation 
Index (3.3 versus 2.4, P<0.001) in addition to a higher 
frequency of NYHA functional class ≥III (37% versus 
21%, P=0.017).
Multivariable ordinal logistic regression analyses for the 
associations with long-term unfavorable QOL and EP are 
presented in Table 4. In an analyses including all patients, 
baseline Zva was independently associated with unfavor-
able QOL (odds ratio [OR], 1.27 per mm Hg·mL−1·m−2; CI, 
1.04–1.57; P=0.023). This finding was confirmed in an 
analysis restricted to surviving patients (n=192; OR, 1.37 
per mm Hg·mL−1·m−2; CI, 1.08–1.73; P=0.010). Also, Zva 
was independently associated with unfavorable EP (OR, 
1.31 per mm Hg·mL−1·m−2; CI, 1.04–1.66; P=0.023). As 
a binary variable, Zva ≥5 mm Hg·mL−1·m−2 was associ-
ated with a 2-fold higher risk of unfavorable QOL (OR, 
1.98 [CI, 1.15–3.41]; P=0.014) and a 2.5-fold higher risk 
of unfavorable EP (OR, 2.55 [CI, 1.41–4.62]; P=0.002).
Changes in Hemodynamics Early and Late After 
TAVR
Table 5 summarizes the echocardiographic and hemo-
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paired analysis of 124 patients. As expected, the aortic 
valve area increased from 0.75±0.21 cm2 at baseline 
to 1.79±0.51 cm2 post-TAVR (P<0.001) and remained 
stable at 1-year follow-up that was associated with a 
reduction of the mean aortic gradient from 41±14 to 
11±4 mm Hg after TAVR and 10±6 mm Hg at follow-
up (P<0.001) and a reduction of the LV mass index 
(113±28, 108±27, 102±27 g/m2; P<0.001). There 
were no significant changes in SVI.
After TAVR, there was a significant reduction in 
systolic and diastolic blood pressure (146±21 ver-
sus 135±19 mm Hg, P<0.001 and 73±12 versus 
69±10 mm Hg, P=0.001, respectively), albeit that at 
follow-up blood pressures approached baseline values 
(140±25 and 75±11 mm Hg, respectively). The pulse 
pressure, however, was lower immediately after TAVR 
and remained so at 1-year. Overall, there was a sig-
nificant increase in systemic arterial compliance (from 
0.56±0.23 mL−1·m−2·mm Hg at baseline to 0.61±0.21 
mL−1·m−2·mm Hg and 0.63±0.26 mL−1·m−2·mm Hg post-
TAVR and 1-year, P<0.042) and a significant decrease 
in Zva (from 5.3±1.6 at baseline to 4.1±1.2 and 4.1±1.2 
mm Hg·mL−1·m−2, post-TAVR and 1-year P<0.001). The 
proportion of patients with a Zva ≥5 mm Hg·mL−1·m−2 at 
baseline decreased significantly post-TAVR (48% versus 
21%, P<0.001) and remained 21% at 1 year.
Table 1. Patient Characteristics According to Baseline Zva in Patients Undergoing TAVR
Baseline Characteristics Total Zva <5 mm Hg·mL−1·m−2 Zva ≥5 mm Hg·mL−1·m−2 P Value
 n=250 n=125 n=125  
Age, y 81±6 80±6 81±6 0.17
Male gender 116 (46) 58 (46) 58 (46) 1.0
Body mass index, kg/m2 27.2±4.9 26.7±4.9 27.8±4.9 0.064
Body surface area, m2 1.87±0.21 1.84±0.20 1.89±0.22 0.064
Diabetes mellitus 74 (30) 31 (25) 43 (34) 0.096
Hypertension 198 (79) 100 (80) 98 (78) 0.76
Hypercholesterolemia 158 (63) 73 (58) 85 (68) 0.12
Creatinine, mmol/L 117±92 122±118 112±55 0.39
Current or recent smoker 148 (59) 73 (58) 75 (60) 0.80
Chronic obstructive pulmonary disease 57 (23) 26 (21) 31 (25) 0.47
Previous malignancy 41 (16) 23 (18) 18 (14) 0.39
Active treatment for malignancy 12 (5) 6 (5) 6 (5) 1.0
Previous falling incident 67 (27) 26 (21) 41 (33) 0.032
Vertigo/dizziness 93 (37) 40 (32) 53 (42) 0.15
Peripheral vascular disease 121 (48) 56 (45) 65 (52) 0.26
Previous myocardial infarction 53 (21) 31 (25) 22 (18) 0.16
Previous coronary artery bypass graft 49 (20) 26 (21) 23 (18) 0.63
Previous percutaneous coronary intervention 80 (32) 37 (30) 43 (34) 0.42
Previous cerebrovascular event 26 (10) 14 (11) 12 (10) 0.68
Cognitive disorder 37 (15) 19 (15) 18 (14) 0.86
Medication
 Betablockers 155 (62) 81 (65) 74 (60) 0.40
 ACE inhibitors/angiotensin receptor blockers 148 (59) 76 (61) 72 (58) 0.66
 Calcium antagonists 56 (23) 36 (29) 20 (16) 0.017
 Nitrates 33 (13) 19 (15) 14 (11) 0.36
 ≥3 antihypertensive medication classes 39 (16) 26 (21) 13 (10) 0.023
Atrial fibrillation 87 (35) 35 (28) 52 (42) 0.024
Permanent pacemaker 24 (10) 12 (10) 12 (10) 0.61
New York Heart Association class ≥III 167 (67) 84 (67) 83 (67) 0.97
Canadian cardiovascular society class ≥II 52 (21) 23 (19) 29 (23) 0.40
Erasmus Frailty score ≥III 68 (27) 33 (27) 35 (28) 0.78
Logistic European System for Cardiac Operative Risk Evaluation, % 17.2±11.6 16.5±10.2 17.9±12.9 0.32
Society of Thoracic Surgeons’ Score, % 5.6±3.3 5.5±3.0 5.6±3.6 0.68
Categorical variables are presented as numbers (percentage), continuous variables are presented as mean±SD. TAVR indicates transcatheter aortic valve replacement; 
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Association Between Zva and QOL at Follow-
Up
Table II in the Data Supplement shows the association 
between Zva post-TAVR and Zva at 1 year with long-
term QOL/EP. Changes in QOL/EP between patients 
with normal and elevated Zva became apparent dur-
ing follow-up. Patients with Zva ≥5 mm Hg·mL−1·m−2 
at 1-year follow-up were more frequently limited 
in mobility, self-care and daily activities (taking a 
shower, walking 100 meter, and walking 1 flight of 
stairs) as also reflected by a worse QOL (median 
EQ-5D index, 0.70 versus 0.81; P=0.008) and worse 
EP (mean exercise limitation index, 3.8 versus 2.5; 
P=0.001) in the context of higher NT-proBNP val-
ues (120 versus 60 mmol/L; P=0.025), as compared 
with patients with Zva <5 mm Hg·mL−1·m−2 at 1-year 
follow-up.
Table 2. Echocardiographic and Hemodynamic Characteristics According to Baseline Zva in Patients Undergoing TAVR
Total Zva <5 mm Hg·mL−1·m−2 Zva ≥5 mm Hg·mL−1·m−2 P Value
n=250 n=125 n=125  
Echocardiographic characteristics
 Left ventricular ejection fraction (%) 54±13 57±12 51±13 0.001
 Left ventricular end-diastolic diameter, mm 53±9 53±10 52±7 0.47
 Left ventricular end-systolic diameter, mm 39±12 39±13 40±11 0.47
Diastolic dysfunction
 Normal or relaxation abnormality 105 (57) 56 (54) 49 (61) 0.37
 Pseudonormal or restrictive 80 (32) 48 (38) 32 (26) 0.36
 No sufficient data 54 (22) 17 (14) 37 (30) 0.002
 Aortic valve area, cm2 0.75±0.21 0.84±0.20 0.66±0.17 <0.001
 Mean aortic gradient, mm Hg 40±14 40±14 38±14 0.14
 Left ventricular outflow tract velocity time index, cm 20±5 22±5 17±5 <0.001
 Left ventricular outflow tract diameter, mm 21±2 22±2 21±2 <0.001
 Stroke volume index, mL/m2 37±10 44±9 30±7 <0.001
 Cardiac index, L/min per m2 2.5±0.7 2.9±0.7 2.1±0.5 <0.001
Left ventricular mass index*
 Gram per square meter 116±32 118±33 114±31 0.32
 Normal or mildly abnormal 145 (61) 71 (61) 74 (61) 1.0
 Moderately abnormal 30 (13) 12 (10) 18 (15) 0.29
 Severely abnormal 64 (27) 34 (29) 30 (25) 0.44
Aortic regurgitation ≥moderate 31 (13) 21 (17) 10 (8) 0.055
Mitral regurgitation ≥moderate 56 (23) 26 (21) 30 (24) 0.57
Hemodynamic characteristics
 Heart rate (beats per minute)† 69±11 67±11 71±12 0.006
 Systolic blood pressure, mm Hg 143±25 141±24 144±25 0.35
 Diastolic blood pressure, mm Hg 76±13 75±12 78±13 0.021
 Mean arterial blood pressure, mm Hg 97±14 93±12 102±14 <0.001
 Pulsatile arterial load, mm Hg 71±21 69±21 72±22 0.20
  Systemic arterial compliance, mL−1·m−2·mm Hg 0.56±0.22 0.68±0.22 0.44±0.13 <0.001
  Systemic vascular resistance, dyne·s·cm−5 1816±598 1449±312 2167±596 <0.001
 Total arterial load, mm Hg·mL−1·m−2 3.78±1.17 2.92±0.47 4.65±1.01 <0.001
  Zva, mm Hg·mL−1·m−2 5.32±1.50 4.19±0.57 6.46±1.25 <0.001
Valve type
 Self-expanding valve 73 (29) 38 (31) 35 (28) 0.73
 Balloon-expanding valve 92 (37) 43 (35) 49 (40)
 Mechanical-expanding valve 83 (34) 43 (35) 40 (32)
Categorical variables are presented as numbers (percentage), continuous variables are presented as mean±SD. TAVR indicates transcatheter aortic valve replacement; 
and Zva, valvulo-arterial impedance.
*Left ventricular mass index (LVMI) was considered normal or mildly abnormal if LVMI was <132 g/m2 in men and <109 in women; moderately abnormal if LVMI was 
131–149 g/m2 in men and 108–122 in women; severely abnormal if LVMI was >148 g/m2 in men and >121 g/m2 in women.
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DISCUSSION
We found that an elevated Zva was present in half of 
the patients with severe AoS undergoing TAVR and was 
found to be associated with an unfavorable long-term 
health-related QOL and EP. Despite significant improve-
ments in Zva following TAVR, 21% of the patients contin-
ued to have an elevated Zva late after TAVR and this was 
associated with an unfavorable QOL and EP.
These findings need to be interpreted in the light of 
the fact that the present study concerns a single-center 
observational series with a rather limited sample size. 
Also, the outcome measure of interest (ie, QOL/EP) 
is of subjective nature notwithstanding the prospective 
use of a standard questionnaire and, therefore, can be 
influenced by other variables some of which are easy 
to define and collect (eg, age, comorbid conditions) but 
some of which are less so such as psychological and 
personality factors and others. For these reasons, we 
also included the Erasmus Frailty Score in our analysis 
which is composed of an extensive geriatric assessment 
that includes data from the Mini-Mental State Examina-
tion, the Malnutrition Universal Screening Tool, hand-grip 
strength, the Katz Index for scoring activities of daily 
living, and the Lawton and Brody index for scoring instru-
mental activities of daily living.15 We indeed found that an 
Erasmus Frailty Score ≥III independently predicts QOL. 
Interestingly, multivariable analysis revealed that not only 
well known comorbid conditions such as chronic obstruc-
tive pulmonary disease, but also both frailty and baseline 
elevated Zva were strong and independent predictors of 
unfavorable outcomes during follow-up.
The question remains to what extent Zva affects 
QOL/EP in patients with AoS treated with TAVR and 
its pathophysiologic basis and, whether, Zva should be 
used in clinical practice, for example, patient selection 
and adjunctive pharmacological therapy. By multivariable 
analysis, we found that an elevated Zva was associated 
with a 2-to-2.5-fold increased risk of unfavorable QOL/
EP at follow-up after TAVR. Obviously, it remains to be 
seen what this point estimate of this risk would be in a 
larger and different population and in the presence of 
a more comprehensive data set of variables potentially 
affecting QOL. In addition, more research is needed to 
define the optimal Zva cutoff value to predict adverse 
outcomes in elderly patients undergoing TAVR, since 
currently available studies found various cutoff levels 
ranging from ≥3.5 up to ≥5.5 mm Hg·mL−1·m2.1,12
Table 3. Association Between Baseline Zva and Long-Term Quality of Life and Exercise Limitation During 
Follow-Up
Parameters at Follow-Up Total Zva <5 mm Hg·mL−1·m−2 Zva ≥5 mm Hg·mL−1·m−2 P Value
All Patients n=250 n=125 n=125  
 EQ-5D utility index* 0.73 (0.22–0.88) 0.77 (0.28–0.88) 0.69 (0.10–0.83) 0.12
Survivors ≥1 y post-TAVR n=192 n=96 n=96  
 EQ-5D (n, % of patients indicating a problem)
  Mobility 150 (80) 67 (71) 83 (88) 0.004
  Self-care 61 (32) 23 (25) 38 (40) 0.019
  Usual activities 121 (64) 58 (62) 63 (67) 0.45
  Pain/discomfort 107 (57) 52 (54) 55 (59) 0.55
  Anxiety/depression 50 (27) 26 (28) 24 (26) 0.74
  Visual analogue score 70 (60–80) 75 (60–85) 70 (55–80) 0.048
  EQ-5D utility index 0.79 (0.60–0.89) 0.80 (0.66–0.92) 0.75 (0.57–0.88) 0.056
 Daily activities (n, % of patients indicating a problem)
  Taking a shower 87 (45) 36 (38) 51 (53) 0.030
  Walking 100 meter 125 (65) 52 (54) 73 (76) 0.001
  Walking stairs (1 flight of) 121 (63) 52 (54) 69 (74) 0.011
  Gardening 134 (70) 64 (67) 70 (73) 0.35
    Exercise limitation index† 2.8±1.7 2.4±1.7 3.3±1.6 <0.001
  New York Heart Association class ≥III 55 (29) 20 (21) 35 (37) 0.017
  NT-proBNP, mmol/L at 1 y‡ 75 (31–180) 69 (24–175) 75 (35–185) 0.23
Categorical variables are presented as numbers (percentage), continuous variables are presented as mean±SD or median (interquartile 
range). EQ-5D indicates EuroQOL-5-dimensions; NT-proBNP, N-Terminal Pro-B-Type Natriuretic Peptide; TAVR, transcatheter aortic valve 
replacement; and Zva, valvulo-arterial impedance.
*Fifty-eight patients who died before quality of life assessment at a median of 7 mo were assigned an EQ-5D utility score of 0. Of these, 29 
patients (50%) had a baseline Zva ≥5 mm Hg·mL−1·m−2.
†Exercise limitation index indicates a summary score with 1 point assigned per limitation in daily activity out of the 5 items that were 
significantly associated with baseline Zva ≥5 mm Hg·mL−1·m−2 by univariable analysis (mobility, self-care, showering, walking 100 meter, walking 
stairs). The index ranges from level 0 to 5 corresponding to (most) favorable vs. unfavorable long-term exercise performance, respectively.




 http://ahajournals.org by on January 30, 2020
Nuis et al Impact of Zva on Quality of Life After TAVR
Circ Cardiovasc Interv. 2020;13:e008372. DOI: 10.1161/CIRCINTERVENTIONS.119.008372 January 2020 8
From a pathophysiologic point of view, the find-
ings of the present study intuitively make sense and 
in particular in the elderly patients referred for TAVR. 
Given the etiology of AoS in such patients (degenera-
tive atherosclerotic process) the correction of the val-
vular load may not suffice to (completely) restore QOL. 
Interestingly, we found that patients with an elevated 
valvuloarterial load also had a lower systemic arte-
rial compliance and a higher systemic vascular resis-
tance and total arterial load. In addition, there was only 
a modest decrease in Zva after TAVR that was also 
reported by Katsanos et al13 and 21% of the patients in 
the present series showed an elevated Zva at >1 year 
after TAVR. The latter may hinder the beneficial effects 
of aortic valve replacement on LV load as suggested 
by higher BNP (B type natriuretic peptide) levels at 1 
year in patients with elevated Zva. Of note, Roşca et al. 
reported higher BNP concentrations in patients with 
aortic stiffness.29
Whether excess arterial afterload can effectively be 
targeted in patients who received TAVR by medical inter-
vention remains uncertain. Similar to Giannini et al,14 we 
found that arterial compliance improved (ie, increase of 
≈12%) during follow-up indicating the potential ben-
eficial effects of adjunctive medical treatment aimed at 
enhancing arterial compliance, thereby, improving QOL. 
Lindman et al31 reported that sildenafil was associated 
with a significant increase in stroke volume due a reduc-
tion of the systemic vascular resistance independent 
of valve load in patients with severe symptomatic AoS 
and normal ejection fraction.30 Also, enalapril has been 
shown to improve symptoms and 6-minute walk test in 
a randomized trial of patients with symptomatic AoS.32
Despite these promising results, routine measures 
aimed at improving arterial afterload are lacking in cur-
rent clinical practice. Nevertheless, clinicians taking care 
of AoS patients may still find Zva useful in improving risk 
stratification and clinical decision-making. Current guide-
lines recommend valve replacement based on valve-spe-
cific criteria (aortic valve area, mean gradient) to define 
severe AoS without addressing the vascular indices of 
excess afterload.33,34 Zva is an easy to obtain measure 
and provides an integrated evaluation of valvular and 
vascular loads with prognostic relevant information in 
patients with asymptomatic moderate/severe AoS1 and 
those undergoing TAVR.13,14 Our findings demonstrate 
that Zva also identifies patients at risk for unfavorable 
long-term QOL, which is sometimes equally important as 
life-expectancy especially in elderly patients who are cur-
rently referred for TAVR.
Limitations
As mentioned above, the present study concerns 
a single-center multidisciplinary prospective study 
during which all variables and outcomes have been 
defined before starting the study (TAVR Care & Cure 
program). Yet, the sample size was rather small and 
might have been subjected to selection bias due to 
the fact that ultrasound data before, after and at 1 
year had to be available of sufficient quality. This also 
held for QOL/EP assessment. Although unfavorable 
Table 4. Multivariable Ordinal Logistic Regression Analyses for Associations Between Baseline Zva and Long-Term 
Unfavorable QOL and EP After TAVR Stratified According to Survival Status
Unfavorable QOL in All Patients 
(n=250)
Unfavorable QOL in Survivors ≥1 
y (n=192)
Unfavorable EP in Survivors ≥1 y 
(n=192)
(According to EQ-5D Utility 
Index*)
(According to EQ-5D Utility 
Index*)
(According to Exercise Limitation 
Index†)
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Age per year 0.99 (0.95–1.03) 0.53 0.99 (0.94–1.04) 0.59 1.02 (0.97–1.07) 0.50
Male gender 1.98 (1.17–3.37) 0.011 1.86 (1.00–3.45) 0.049 1.63 (0.89–2.98) 0.12
Chronic obstructive pulmonary disease 2.63 (1.42–4.85) 0.002 1.66 (0.82–3.39) 0.16 3.40 (1.65–7.0) 0.001
Peripheral vascular disease 1.48 (0.89–2.46) 0.14 0.71 (0.38–1.33) 0.29 0.72 (0.40–1.32) 0.29
Aortic valve area, per cm2 2.19 (0.44–10.9) 0.34 0.89 (0.78–15.1) 0.21 0.59 (0.10–3.60) 0.57
Baseline NYHA class, per category 1.77 (1.21–2.58) 0.003 1.76 (1.12–2.78) 0.014 2.08 (1.32–3.26) 0.001
Erasmus frailty score ≥III 2.23 (1.31–4.00) 0.004 4.05 (1.98–8.30) <0.001 2.49 (1.26–4.92) 0.009
Time to death or measurement of EQ-5D-index/
exercise limitation index, per month
0.94 (0.92–0.95) <0.001 1.04 (1.01–1.06) 0.008 1.02 (1.0–1.05) 0.12
Zva, per mm Hg·mL−1·m−2 ‡ 1.27 (1.04–1.57) 0.023 1.37 (1.08–1.73) 0.010 1.31 (1.04–1.66) 0.023
Zva ≥5 mm Hg·mL−1·m−2‡ 1.98 (1.15–3.41) 0.014 1.93 (1.06–3.52) 0.031 2.55 (1.41–4.62) 0.002
EP indicates exercise performance; EQ-5D, EuroQOL-5-dimensions; NYHA, New York Heart Association; OR, odds ratio; QOL, quality of life; TAVR, transcatheter 
aortic valve replacement; and Zva, valvulo-arterial impedance.
*EQ-5D utility index was categorized in level 1 to 4 corresponding to (most) favorable vs unfavorable long-term quality of life, respectively.
†Exercise limitation was categorized in level 0 to 5 corresponding to (most) favorable vs unfavorable long-term exercise performance, respectively.
‡All multivariable odds ratios are based on the inclusion of Zva as continuous variable. The odds ratio for Zva ≥5 mm Hg·mL−1·m−2 was obtained by using this variable 
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QOL as measured by the EuroQOL questionnaire con-
cerns a well-validated tool in cardiovascular medicine, 
the use of the exercise limitation index (consisting of 
items from EQ-5D instruments and questions related 
to physical fitness) lacks validation and, thus, concerns 
a limitation in this study. Nevertheless, it should be 
noted that dedicated assessment tools for such pur-
poses specifically designed for, and validated in elderly 
patients undergoing TAVR are currently not available. 
Of note, blood pressure data were not collected dur-
ing the echocardiographic assessment and may have 
influenced the assessment of Zva albeit that the fre-
quency of elevated Zva at baseline and early and late 
after TAVR was similar in this and other studies.13 Also, 
certain conditions such as atrial fibrillation are known 
to affect the quantification of Zva as SVI estimation 
is dependent on the average of multiple CW Doppler 
tracings. At last, moderate/severe aortic regurgitation 
generally increases systolic blood pressure and mean 
gradient both affecting Zva quantification.1
Conclusions
Baseline elevated Zva in patients with AoS undergoing 
TAVR exists in half of the patients and has unfavorable 
impact on health-related QOL and EP at long-term 
follow-up. Despite successful TAVR, one-fifth of the 
patients has elevated Zva during early and long-term 
follow-up and remains associated with impaired QOL 
and EP.
Table 5. Echocardiographic and Hemodynamic Changes Before, After, and at 1-Year Follow-Up After TAVR (Subanalysis 
124 Patients)
Pre-TAVR Post-TAVR 1 y After TAVR P Value P Value P Value
n=124 n=124 n=124 (Pre vs Post) (Pre vs 1-y) (Post vs 1-y)
Echocardiographic characteristics
 Left ventricular ejection fraction, % 56±11 56±11 53±13 1.0 0.19 0.17
 Left ventricular end-diastolic diameter, mm 52±7 50±7 51±7 0.017 0.19 1.0
 Left ventricular end-systolic diameter, mm 38±11 36±9 36±9 0.43 1.0 1.0
Diastolic dysfunction
 Normal or relaxation abnormality 60 (65) 58 (73) 64 (74) 0.39 0.12 1.0
 Pseudonormal or restrictive 32 (35) 22 (28) 23 (26) 0.39 0.12 1.0
 No sufficient data 32 (35) 44 (35) 37 (30) NA NA NA
Aortic valve area, cm2 0.75±0.21 1.79±0.51 1.77±0.48 <0.001 <0.001 0.99
Mean aortic gradient, mm Hg 41±14 11±4 10±6 <0.001 <0.001 0.43
Left ventricular outflow tract velocity time index, cm 20±5 20±5 20±5 1.0 0.86 0.94
Left ventricular outflow tract diameter, mm 21.0±2 21.2±2 21.5±2 0.61 0.004 0.055
Stroke volume index, mL/m2 38±11 39±11 38±10 1.0 1.0 1.0
Stroke volume index <35 mL/m2 50 (40) 52 (42) 47 (38) 0.88 0.76 0.51
Left ventricular mass index*
 Gram per square meter 113±28 108±27 102±27 0.30 <0.001 0.054
 Normal or mildly abnormal 79 (67) 81 (71) 85 (74) 0.56 0.28 0.70
 Moderately abnormal 14 (12) 12 (11) 13 (11) 0.82 1.0 0.66
 Severely abnormal 25 (21) 21 (18) 17 (15) 0.77 0.12 0.21
Aortic regurgitation ≥moderate 15 (12) 6 (5) 10 (8) 0.049 0.50 0.29
Mitral regurgitation ≥moderate 19 (15) 19 (16) 26 (21) 1.0 0.17 0.14
Hemodynamic characteristics
 Systolic blood pressure, mm Hg 146±21 135±19 140±25 <0.001 0.061 0.22
 Diastolic blood pressure, mm Hg 73±12 69±10 75±11 0.001 0.45 <0.001
 Mean arterial blood pressure, mm Hg 97±14 90±11 97±13 <0.001 1.0 <0.001
 Pulsatile arterial load, mm Hg 73±20 66±16 64±23 0.002 0.004 1.0
 Systemic arterial compliance, mL−1·m−2·mm Hg 0.56±0.23 0.61±0.21 0.63±0.26 0.11 0.042 1.0
 Total arterial load, mm Hg·mL−1·m−2 3.8±1.2 3.4±1.0 3.5±1.0 0.012 0.12 1.0
 Zva, mm Hg·mL−1·m−2 5.3±1.6 4.1±1.2 4.1±1.2 <0.001 <0.001 1.0
Categorical variables are presented as numbers (percentage), continuous variables are presented as mean±SD. TAVR indicates transcatheter aortic valve replacement; 
and Zva, valvulo-arterial impedance.
*Left ventricular mass index (LVMI) was considered normal or mildly abnormal if LVMI was <132 g/m2 in men and <109 in women; moderately abnormal if LVMI was 
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